$58.0M
The Series A round was led by Ahren, OMX Ventures, and Paladin Capital Group to develop biomanufacturing platforms.
"Synthetic genomics is redefining how we harness biology. Our suite of proprietary technologies and incomparable team allows us to build novel materials and products that will revolutionise drug manufacturing and discovery,"

